Stratified analysis indicated only in MM that the median overall survival (OS) time for patients with EZH2 gain was significantly shorter than that without EZH2 gain (21.20 vs. 46.63 months; p = 0.018, Figure 2B) (in acral melanoma (AM): 64.70 vs. 80.50 months; p = 0.450, Figure 2C) (in CM: 149.90 vs. 92.37 months; p = 0.825, Figure 2D). Here, EZH2 is linked to Miyoshi myopathy.